1. The central conclusion: Neko Health is more interesting as an attempt to redesign the production system of outpatient healthcare than as a premium “body-scan clinic.”

Neko Health was co-founded in Stockholm in 2018 by Daniel Ek and Hjalmar Nilsonne. Their roles were asymmetric from the beginning. Ek was the originator of the problem, an early source of capital, a strategic driver, and an unusually powerful source of brand credibility. Nilsonne became the full-time CEO and the operating founder responsible for turning the concept into medical devices, software, clinics, and a clinical organization. Neko itself describes its mission not simply as scanning, but as engineering a preventive healthcare system using proprietary devices, real-time data science, and a clinical model designed around healthy people rather than only sick patients.

The Neko proposition can be compressed into one idea: take health information that has traditionally been fragmented across dermatology, cardiovascular testing, laboratories, primary care, health-management services, and wearables; collect much of it within a standardized roughly 60-minute visit; then repeat the process annually to create longitudinal health data. This is also the key distinction between Neko and companies such as Prenuvo. Neko is not a whole-body MRI or CT service. It combines high-resolution skin imaging, optical and thermal sensing, ECG and cardiovascular measurements, blood pressure, rapid blood analysis, body-composition measures, and other sensor data, with a clinician interpreting the results.

As of September 10, 2026, Neko has grown from its first Stockholm clinic in 2023 to a multi-site operation in Sweden and the UK. The company says more than 100,000 people have been scanned and more than 350,000 have registered or joined waiting lists. Roughly 75% of members, on average, book and prepay for the following year's scan at the end of their first visit. In July 2026 it raised a $700 million Series C. The company did not officially disclose the valuation; the Financial Times, citing people familiar with the transaction, reported a valuation of almost $7 billion.

Neko's core asset therefore is not merely a futuristic scanner. It is attempting to build an integrated system of hardware, software, clinical protocols, clinic operations, physician workflow, consumer branding, and longitudinal health data. That vertical-integration philosophy is one of the clearest elements Daniel Ek appears to have carried from his experience building Spotify into healthcare.

2. Hjalmar Nilsonne: the founder who is closest to Neko's day-to-day operating core.

Reliable public information on Nilsonne's exact date and place of birth, and on his family's financial circumstances, is limited / cannot currently be confirmed. The Times described him as 38 in April 2025, which suggests a birth year around 1986–1987, but that is not sufficient to establish an exact date.

What can be established with considerably more confidence is that he grew up in an intensely medical family. Nilsonne told GQ that both of his parents, his grandfather, and his older brother belonged to the medical world; The Times describes his family as one of doctors and medical scientists. Medicine was so normal in his environment that adults asked him what kind of doctor he intended to become.

The effect was paradoxical. Watching the pressure his parents experienced in medicine pushed him away from the field. He gravitated instead toward computers, programming, and engineering. This distinction matters: Neko was not built by a physician who gradually became an entrepreneur; its operating founder was an engineer who had deliberately moved away from medicine and was eventually persuaded to return to it as a systems problem. That helps explain why Neko approached healthcare as a question of sensors, throughput, automation, and workflow rather than simply opening another conventional private clinic.

Nilsonne holds an MSc in Industrial Engineering, with public speaker biographies describing a focus on energy systems and machine learning. The institution awarding the degree is not sufficiently consistently identified in the reliable sources reviewed here, so it is not stated as fact.

His initial professional obsession was not healthcare but climate and the energy transition. The Times reports that, after his industrial-engineering education, he became deeply interested in climate change and founded two companies related to the shift toward renewable energy. Public biographies consistently identify Watty; the identity of the second company is not sufficiently clear in the available public material.

Watty was an energy-data company using machine learning to improve residential energy efficiency. Nilsonne co-founded the company and served as CEO. Official speaker biographies from Brilliant Minds and SXSW London say it was later acquired by ASSA ABLOY.

There is a strong intellectual continuity between Watty and Neko. Watty attempted to use sensing, data, and machine learning to understand inefficiency inside a complex physical system; Neko applies similar engineering instincts to the human body and to clinical workflow. In structural terms, Nilsonne brought Neko experience in sensing, machine learning, systems engineering, hardware-software integration, and industrialized data collection, rather than a medical license. This is an inference from his documented career path.

3. Daniel Ek: Neko's second genetic strand comes from Spotify—low latency, consumer experience, and scale.

Daniel Georg Ek was born in Stockholm on February 21, 1983, and grew up in Rågsved, in southern Stockholm. His upbringing is generally described as far removed from elite finance or technology circles; he was largely raised by a single mother who worked in childcare.

His family did not provide a conventional technology or investment network. Instead, computers became his early lever. Reporting on his childhood describes him receiving a guitar at four and a computer at five, learning programming early, and building websites for clients as a teenager. He also reportedly sought a job at Google as a teenager and was rejected because he lacked a university degree.

Ek completed secondary school in 2002 and enrolled in engineering at the KTH Royal Institute of Technology, but left after a very short period—commonly reported as roughly eight weeks—to pursue his technology career. He therefore did not complete a conventional university degree.

Before Spotify, he accumulated a series of early Nordic internet experiences: work at search-marketing company Jajja, a senior position at Tradera, later acquired by eBay, a role as CTO of Stardoll, and the founding of online advertising company Advertigo. Advertigo was acquired by TradeDoubler in 2006. Ek also briefly worked around µTorrent, where he collaborated with developer Ludvig Strigeus.

In 2006, Ek and TradeDoubler co-founder Martin Lorentzon created Spotify, which formally launched in 2008. Spotify's fundamental proposition was not merely to “sell music,” but to turn the consumer demand demonstrated by piracy—instant access, very little friction, and extraordinary breadth of choice—into a legal product. Streaming subsequently became one of the dominant modes of global music consumption.

That experience visibly influenced Neko. Ek has framed healthcare as containing problems analogous to the early music industry: much of the necessary technology exists, but the customer experience is fragmented, latency is high, and legacy institutions are organized around inherited processes. Neko summarizes his founding question as: if no healthcare system existed and we had to design one today, what would it look like?

Healthcare was also not an arbitrary new sector for Ek. Reporting describes years of personal interest in medical and genetics research and experimentation with health devices. His stated objective has been less about maximizing lifespan at any cost than about increasing healthspan—the portion of life spent in good health.

In 2021, Ek also established Prima Materia, a long-duration company-building and investment platform. Prima Materia describes itself as a European organization that builds and develops companies for the long term. It was also an important early capital platform for Neko: Neko's official 2023 Series A announcement specifically said that round was its first external financing, while identifying Prima Materia as an original investor.

By 2026, Ek was no longer Spotify's CEO. Beginning in January 2026 he became Executive Chairman, while Gustav Söderström and Alex Norström became co-CEOs, allowing Ek to focus more heavily on long-term strategy and capital allocation. That transition increases the strategic importance of Neko, Prima Materia, and Ek's other long-duration projects within his overall career portfolio.

4. Why the two founders came together: one was actively searching for a healthcare problem; the other had spent much of his life avoiding healthcare.

The origin story dates to roughly April 10, 2018. Ek later published the story of sending Nilsonne a direct message proposing that they start a healthcare company. They did not know each other particularly well, and Nilsonne's initial response was an unenthusiastic “perhaps.”

Nilsonne later told The Times that his reaction to the healthcare idea was close to immediate resistance. His message to Ek was essentially: it is a good idea, but do not do it with me—you underestimate how difficult this industry is to change.

Ek changed the question from “will you join me?” to something closer to: if you were going to do it, how would you approach it? A series of conversations followed, gradually reframing the project from “start a healthcare company” to “design a healthcare system from first principles.”

Their answer was to design around healthy people rather than only patients already presenting with disease; capture signals earlier rather than waiting for symptoms; consolidate fragmented testing; and give clinicians enough time to explain what the data actually means.

That division of labor has largely persisted. Nilsonne is the CEO and operating founder. Ek is closer to chairman, strategic founder, early capital provider, and source of product philosophy and network leverage. Describing Neko simply as a “side project from Spotify's founder” understates Nilsonne's role. Ignoring Ek's capital, credibility, recruiting reach, investor network, and experience with consumer-scale technology equally fails to explain how Neko could spend roughly five years developing physical and clinical infrastructure before large-scale commercialization.

Company, capital, and business structure

5. From 2018 to 2023, Neko chose an unusually non-SaaS path: roughly five years of physical technology development before opening to consumers.

Neko did not immediately launch a wellness app or simple blood-testing service after its 2018 formation. The company says it spent the period developing proprietary sensors, real-time data systems, and a new clinical operating model. Its first consumer clinic did not open until February 2023 in Stockholm.

That meant the first several years were devoted primarily to infrastructure rather than customer acquisition. Nilsonne has since described the company as spending around five years working through what an entirely new physical infrastructure layer for healthcare should look like.

At commercial launch in 2023, Neko said the core scan itself took about ten minutes, with more than 70 sensors collecting roughly 50 million data points in minutes, followed by a physician consultation. The service initially cost around €250. The first Stockholm appointments sold out in less than two hours, the waiting list exceeded 10,000, and about 80% of early members rebooked for the following year.

Over time, the product definition evolved from a “ten-minute scan” to an approximately 60-minute healthcare experience, because the complete visit includes scanning, rapid blood analysis, clinician interpretation, and recommendations. This explains why public sources variously refer to ten-, fifty-, or sixty-minute experiences: they are often measuring different segments of the same workflow.

6. Technology: Neko's defensibility appears to lie primarily in integration and workflow rather than in claiming a single universal imaging breakthrough.

Neko currently identifies Derma, Spectrum, Echo, and Neko Lens as core proprietary devices. It says these systems are designed, engineered, and assembled in Stockholm, with clinical researchers and engineers working in close physical proximity so that clinical observations can rapidly become hardware iterations.

The Derma system supports high-resolution full-body skin imaging and longitudinal mole mapping; Neko currently says it captures more than 2,000 high-resolution skin images. Echo, ECG, and multi-point blood-pressure measurements contribute cardiovascular information. Spectrum focuses on circulation and microcirculatory signals. On-site blood analysis means selected biomarkers can be available during the same visit rather than days later.

In 2026, Neko added body-composition analysis, including measures such as body-fat and visceral-fat estimates, and began allowing clinicians to incorporate Apple Health information such as steps, sleep, and heart-rate variability. This represents a meaningful shift from a yearly “snapshot” toward a more continuous health-data platform.

The company also began deploying second-generation Derma-2, Echo-2, and Spectrum-2 systems at a new Stockholm clinic, designed to collect greater volumes and higher-fidelity signals while automating more repetitive clinical work.

Axios made an important observation: many of the underlying technologies Neko uses already exist; its differentiation is in putting them together inside a single product and automating parts of primary-care testing that were previously performed manually and separately. That is a more accurate characterization of Neko's advantage than saying it invented one revolutionary universal scanner.

Structurally, Neko therefore resembles a vertically integrated consumer-technology company applied to healthcare. It develops parts of the devices, software, analytics, app, clinic environment, clinical protocols, and patient experience itself, while keeping clinicians as the final interpreters of the health information. The company explicitly identifies vertical integration as foundational to its model.

7. What are the real assets? They are company-level technical and clinical systems, not a collection of clinics personally owned by Daniel Ek.

The first asset class is proprietary technology: Derma, Spectrum, Echo, Neko Lens, their second-generation successors, and the associated software, analytics, and clinical interfaces. Neko explicitly says it develops hardware, software, and the consumer experience in-house.

The second is operating infrastructure: standardized scan rooms, on-site labs, clinic layouts, and workflows that allow data collection, laboratory testing, interpretation, and next-step planning to occur within one visit. In 2026 the company also began testing a modular second-generation scan-room platform to improve replicability.

The third is brand equity. Neko deliberately rejects the visual and emotional cues of a conventional hospital, using designed interiors, rapid service, and consumer-technology-style interfaces to reduce friction around health screening. Vogue has described its market position as “affordable luxury”—cheaper than many elite longevity offerings but intentionally premium in experience.

The fourth is longitudinal data. Annual repeat visits allow skin, blood, cardiovascular, circulatory, and body-composition results to be compared against the same person's historical baseline. Wearable integration can begin filling the gap between annual visits. The use of such information remains subject to consent, privacy law, and regional medical-data regulation; it should therefore not be described as an unrestricted corporate right to monetize all member health data.

The fifth asset is organizational and clinical talent. In 2026 Neko said it employed more than 1,000 doctors, researchers, and engineers, with more than half of the organization in clinical roles. Its medical leadership includes former Amazon Health CMO Dr. Sunita Mishra and former NHS England National Medical Director for Primary Care Dr. Nikita Kanani MBE.

These are assets and organizational capabilities of Neko Health, not assets that can automatically be attributed personally to Ek or Nilsonne. Their precise post-Series-C ownership percentages, voting rights, and complete capitalization table have not been publicly disclosed; public information is limited / cannot currently be confirmed.

8. Capital structure: Neko evolved from a company Daniel Ek could fund patiently into a shared bet by elite global venture capital and influential individual investors.

The initial capital base came from Ek and the Prima Materia ecosystem. The company's 2023 financing announcement explicitly described its Series A as the first time Neko accepted outside capital, implying that its long pre-launch development phase had been supported by founder-associated capital.

In July 2023, Neko raised a €60 million Series A, led by Lakestar, with participation from Atomico and General Catalyst. Lakestar founder Klaus Hommels and Atomico founder Niklas Zennström joined the board.

The composition was significant: the first external round was driven not primarily by traditional medical conglomerates but by major European and US technology investment firms. That reinforced Neko's identity as a technology-led redesign of healthcare rather than a conventional clinic operator.

In January 2025, Neko raised a $260 million Series B, led by Lightspeed Venture Partners, with General Catalyst, O.G. Venture Partners, Rosello, Lakestar, and Atomico participating. Lightspeed's Bejul Somaia joined the board.

Public reporting disagreed slightly on the valuation. The Financial Times and The Times put it at about $1.7 billion, while Axios cited a source giving $1.8 billion; the company itself did not confirm the figure. The appropriate conclusion is therefore that media estimates placed the post-Series-B valuation at roughly $1.7–$1.8 billion, with differing reports.

In July 2026, Neko completed a $700 million Series C. Lightspeed led and O.G. Venture Partners co-led, with existing investors Atomico, General Catalyst, and Lakestar joined by Liberty City Ventures, Positive Sum, and BDT & MSD. O.G.'s David Ofer was expected to join the board subject to regulatory approval.

The Series C also brought a striking group of individual investors: Mark Zuckerberg and Priscilla Chan, Ari Emanuel, Jimmy Iovine, Maria Sharapova, Thierry Henry, Tim Ferriss, will.i.am, Danny Meyer, Claudia Schiffer, Matthew Vaughn, and others. Existing individual backers included Alexis Ohanian, Gary Vaynerchuk, Katie Haun, Steven Bartlett, and Zoë Saldaña.

For a direct-to-consumer health company dependent on trust and habit formation, these people provide more than cash. Their networks across Silicon Valley, entertainment, sports, hospitality, and wellness can function as influence capital and distribution credibility in addition to financial capital. That is a commercial inference from the investor mix.

The three disclosed external rounds together amount to more than $1 billion equivalent before counting founder-era funding. Neko did not disclose an official Series C valuation; the Financial Times reported, based on people familiar with the transaction, that it was almost $7 billion. That number should be treated as a reported private-market valuation rather than an officially confirmed figure.

9. Business model: Neko is not conventional subscription SaaS, but it is turning periodic screening into subscription-like annual behavior.

Its immediate revenue source is self-pay preventive assessment. As of the research date, the official price is £299 in the UK, 2,750 SEK in Sweden, and $499 for the SoHo, New York clinic scheduled to open on September 24, 2026.

The core model is consumer-directed rather than centered on traditional reimbursement. Neko sells speed, convenience, design, integrated measurement, and early detection. In that sense one of its biggest competitors is not another clinic but the behavioral instinct of a healthy person to ask: “I feel fine, so why should I pay for a health assessment?”

The most important economic variable is repeat behavior. Neko reported roughly 80% rebooking in its early Stockholm phase and still around 80% after reaching 10,000 scans. By 2026, with more than 100,000 completed scans, it reported an average of 75% of members booking and prepaying the following year's scan at the end of their first appointment.

That creates a highly attractive structure. It may not be a contractual auto-renewing subscription, but behaviorally it resembles annual recurring healthcare. Prepayment improves cash conversion; repeat use reduces the need to reacquire the customer; and later scans become more informative because they compare a person against his or her own history rather than only against population averages. The latter points are business-model inferences.

A second key variable is information captured per unit of clinical time. Nilsonne has said the company has engineered the workflow to extract as much high-quality health information as possible within an hour, allowing it to charge a relatively accessible price while retaining healthy margins.

By 2026, Ek told the Financial Times that every Neko clinic operating for more than six months was profitable on a gross-margin basis. That does not mean the overall company is profitable—Neko continues to spend heavily on R&D, new sites, staffing, and US expansion—but it suggests mature individual clinics may have a replicable positive unit model.

Longer term, the business model may evolve from “sell one scan each year” toward a persistent health operating system: the physical visit becomes a high-quality annual anchor; the app, Apple Health, Oura, Whoop, and Apple Watch can provide signals between visits; clinicians and algorithms turn those signals into interpretation and action. The 2026 wearable integration is an early step in precisely that direction.

Results, controversies, and current position

10. Timeline and turning points: Neko's value inflected through four major stages.

The first stage, 2018–2022, was stealth development. Ek recruited Nilsonne in 2018 and they settled on a first-principles preventive-health thesis. Rather than rushing to market, they invested years in hardware, software, and the clinical operating model. That sacrificed short-term speed but meant Neko emerged as physical healthcare infrastructure rather than a concept-only health app.

The second stage was product-market validation in 2023. The first Stockholm location opened in February. Initial appointments sold out in under two hours and the waiting list passed 10,000. In July, Neko accepted institutional outside capital for the first time through its €60 million Series A. The company thereby moved from a founder-backed research project into an investable commercial platform.

The third stage, 2024–2025, demonstrated early international replicability. Neko entered London and added UK capacity. By the January 2025 Series B it had completed about 10,000 scans and accumulated a global waiting list above 100,000. When its Spitalfields clinic opened in April 2025, the company said it had passed 15,000 scans and that the site could support roughly 30,000 annually.

The fourth stage, 2026, is the scale-capital and US phase. Neko introduced new hardware, body composition, and wearable integration, raised $700 million in July, and formally announced its first American clinic in August. The SoHo clinic is scheduled to open on September 24, 2026; therefore, on the research date of September 10, 2026, it is not yet officially open. More than 25,000 New Yorkers were already on the waiting list at announcement.

The United States strategy extends beyond one clinic. Neko says it plans additional New York locations, followed by Miami, Washington, D.C., and San Francisco. The next test is therefore no longer whether consumers want the product, but whether Neko can replicate a heavily integrated clinical model inside the more expensive and complex US medical environment.

11. Most important achievements: Neko has already demonstrated demand and commercialization, but commercial validation is not the same as validated long-term clinical outcomes.

Its strongest commercial proof is consumer demand. The trajectory from a first clinic selling out in under two hours and generating a 10,000-person queue, to a 100,000-person waitlist in 2025 and more than 350,000 registered or waiting by 2026, with over 100,000 scans completed, demonstrates that a meaningful population is willing to pay for proactive information while still ostensibly healthy.

The second achievement is retention. A 75%–80% propensity to commit to another annual visit is unusually consequential for a consumer-health business. It suggests Neko is not relying only on curiosity surrounding a futuristic experience; many users see enough value to turn it into a routine.

The third achievement is product packaging and price compression. Neko combines skin assessment, cardiovascular measurements, blood testing, physical metrics, and clinician interpretation in about one hour for £299 in the UK. That does not make preventive medicine universally inexpensive, but it creates a price category far below many multi-thousand-dollar longevity programs and whole-body MRI offerings.

A fourth result comes from first-year detection data. According to The Guardian's reporting on Neko's first 2,707 Stockholm users aged 22 to 75, around 14% required additional medical attention or monitoring, and roughly 90% of those individuals were previously unaware of the issue; about 1% were categorized as having findings with potentially life-saving significance. These are operational company data, not randomized evidence of population-level benefit.

In 2025 Neko published data on its first 1,469 returning members, scanned roughly one year apart, showing improvements in selected measures such as blood pressure, cholesterol, and glucose. Crucially, the company itself stated that this was not a scientific study with a control group. The data can therefore show that certain indicators improved in returning members; it cannot by itself establish that Neko caused those improvements.

In 2026 the company further reported that three in four returning members whose first scans had identified severe or life-threatening conditions were either in good health or had those conditions under control, and that five of seven selected biomarkers improved significantly between scans. The same caveat applies: these are company-reported real-world outcomes, not independent randomized evidence of causality.

Neko is running more formal research. Its portfolio includes SCAPIS 2 Spectrum, SCAPIS 2 Cardio, and the MIND study in type 1 diabetes, with work at Danderyd Hospital examining areas such as microcirculation, arterial stiffness, vascular aging, and possible early cardiovascular signals.

The most defensible current conclusion is therefore: Neko has demonstrated that consumers will pay, will return, that mature clinics may achieve positive gross margins, and that the system identifies previously unknown abnormalities. It has not yet conclusively demonstrated that annual Neko scanning in a general asymptomatic population reduces long-term mortality or major-disease incidence. That larger proposition requires longer-term and more independent clinical evidence.

12. Controversies and failure modes: the fundamental question is not whether Neko feels futuristic, but when more health information actually translates into better medicine.

The first controversy concerns false positives, overdiagnosis, and downstream medical burden. When large numbers of measurements are performed on healthy, asymptomatic people, some abnormalities may ultimately prove harmless but still require repeat testing, specialist referrals, or invasive workups. Experts interviewed by The Guardian raised the possibility that private screening could generate follow-up work for systems such as the NHS. Neko argues that clinician triage should help ensure only meaningful findings are referred onward.

The second issue is algorithmic transparency and validation. Experts cited by The Guardian asked for more transparency around AI training and methodology. Neko does not position AI as an autonomous physician—the final results are interpreted by clinicians—but once algorithms help prioritize images and physiological signals, sensitivity, specificity, performance across populations and skin tones, and real-world false-negative rates become critical issues for scale.

The third issue is the line between preventive medicine and a health-anxiety industry. GQ's reporting on the broader full-body-screening sector describes the underlying tension: some users obtain genuinely important early diagnoses; others may receive ambiguous information that generates additional anxiety and testing without clear benefit. Neko is less expensive than full-body MRI services but still participates in this broader consumer market for proactive medical information.

The fourth issue is accessibility. Neko repeatedly says longevity should not be reserved for billionaires. Prices of £299, 2,750 SEK, and $499 are indeed far below many elite full-body MRI and concierge-longevity offerings, but they remain out-of-pocket expenditures. Vogue's description of the business as “affordable luxury” captures the position accurately: Neko is not public healthcare; it is attempting to bring what was once very high-end preventive medicine down toward an upper-mass-market consumer price point.

The fifth risk is capital intensity. Neko is not pure software. It must design and manufacture equipment, operate laboratories, lease and build clinics, hire clinicians and technical staff, and navigate medical regulation across jurisdictions. The $700 million Series C demonstrates extraordinary investor confidence, but it also reflects how much capital global replication of the model may require. The US will be an especially important test of whether the vertically integrated model can preserve several-hundred-dollar pricing and healthy clinic-level economics.

In the available public reporting, the principal Neko-specific controversies are therefore about clinical evidence, overdiagnosis, false positives, AI transparency, downstream health-system burden, and equity of access, rather than a major public legal, copyright, or co-founder dispute.

Daniel Ek has separate reputational controversies that should not be conflated with Neko: disputes over artist economics and content at Spotify, and criticism surrounding Prima Materia's large investments in European defense-AI company Helsing, which contributed to some musicians distancing themselves from Spotify. Those controversies concern Ek's wider business and capital activities, not evidence of wrongdoing by Neko Health.

13. Current position and real-world influence: Neko has moved well beyond the “concept startup” stage, but it has not yet become healthcare infrastructure.

As of September 10, 2026, Neko has a substantial European physical footprint. Its official site lists UK locations in London's Covent Garden, Spitalfields, Marylebone, and Victoria, plus Birmingham and Manchester, along with two Stockholm sites at Mood and Östermalmstorg. Although the New York Lafayette/SoHo location is already marketed and taking registrations, its official opening date is September 24, 2026, so it remains a forthcoming location as of this research date.

The first US clinic, at 300 Lafayette Street, will span two floors and contain seven scan rooms, with a $499 price. More than 25,000 New Yorkers had already joined the waiting list when the opening was announced. Neko says additional New York sites will follow, then Miami, Washington, D.C., and San Francisco.

The company now reports more than 1,000 doctors, researchers, and engineers; more than 100,000 people scanned; over 350,000 registrations or waitlist members; and a $700 million latest financing round. With private-market reporting placing its valuation near $7 billion, Neko has moved from early health-tech startup to a well-capitalized growth-stage medical technology and clinic platform pursuing multinational expansion.

Nilsonne remains the central day-to-day operator: co-founder and CEO, integrating engineering, medicine, clinic execution, and international expansion. Ek functions more as a founder-chairman, strategic architect, and capital-and-network multiplier. His importance is not that he manages individual clinics, but that he posed the initial question, absorbed early long-duration risk, and imported a consumer-experience and scaling mentality shaped by Spotify.

Neko's most important contribution so far is not the invention of a single new medical test. It is a new packaging and operating model for preventive healthcare: measurements that once required separate appointments, locations, and waiting periods are reorganized into a standardized, rapid, highly designed, repeat-purchase service. Axios's observation that many underlying technologies already existed, while Neko's differentiation lies in integration and automation, is central to understanding where its real innovation sits.

If long-term clinical research eventually demonstrates net health benefits and mature clinics continue generating attractive unit economics, Neko could evolve beyond a screening chain into a form of preventive primary-care infrastructure: consumers continuously collect and understand health information while conventional hospitals focus more intensely on disease that actually requires treatment. That is Neko's most ambitious structural proposition—and the part that remains least fully proven today.

The most accurate final characterization is therefore:

Daniel Ek originated the problem and supplied capital, credibility, and a scaling philosophy; Hjalmar Nilsonne engineered the operating system; Neko turned preventive medicine into a vertically integrated consumer product built around proprietary sensors and standardized clinics; and investors are now betting that this model can be replicated from Europe into the United States and ultimately much more broadly.

Neko has already demonstrated demand, repeat behavior, brand strength, and early clinic-level economics. The next phase must demonstrate something harder: durable clinical net benefit, efficient international replication, and long-term healthcare value.